Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7624 in COPD Patients With Frequent Exacerbations
NCT02238483Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD7624 with Placebo (2 arms). Primary endpoint: Time to First Moderate to Severe COPD Exacerbation or Early Drop-out Related to Worsening of COPD Symptoms at 12 weeks. Started Oct 2014; status: completed.
02
Drugs
AZD7624
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02238483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238483.